Gyre Therapeutics (GYRE) Liabilities and Shareholders Equity (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $162.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 24.83% year-over-year to $162.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $640.2 million (up 27.69% YoY) and the FY2025 annual result came in at $166.1 million, up 32.48% from the prior year.
• Liabilities and Shareholders Equity retreated to $162.0 million in Q1 2026 per GYRE's latest filing, from $166.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $166.1 million in Q4 2025 and bottomed at $10.0 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $120.9 million (2024), against an average of $97.7 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity sank 85.13%; it then soared 1156.92% in 2024.
• Tracing GYRE's Liabilities and Shareholders Equity over 5 years: stood at $84.8 million in 2022, then surged by 37.5% to $116.5 million in 2023, then rose by 7.61% to $125.4 million in 2024, then jumped by 32.48% to $166.1 million in 2025, then slipped by 2.48% to $162.0 million in 2026.
• Per Business Quant, the three latest GYRE Liabilities and Shareholders Equity figures stand at $162.0 million (Q1 2026), $166.1 million (Q4 2025), and $159.4 million (Q3 2025).

Peer Comparison